Tafenoquine and Babesiosis…a step closer to wellness?
If you have the coinfection of Babesiosis, this is an important episode of Lyme Time for you. Learn how ticks can spread this insidious parasite infection and how the symptoms present. Dr. Geoffrey Dow has devoted much of his research in testing the drug Tafenoquine (currently FDA approved for Malaria) because Babesiosis becomes very similar to Malaria once it causes infection.
Babesiosis typically encompasses symptoms such as shortness of breath (air hunger), cough and flu-like symptoms but can also be asymptomatic. It is also possible to experience Relapsing Babesiosis. If combined with Lyme disease, it can develop into a constellation of symptoms including cardiac tickborne illness.
Dr. Dow explains how Tafenoquine can target these parasites post-exposure and shares research regularly with Yale, Rhode Island Medical Center and Tufts, amongst others. Tune in to hear good news about this possible treatment as he awaits final FDA approval.
Geoffrey Dow is the CEO, President, and sole Director of 60 Degrees Pharmaceuticals, Inc. He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60 Degrees Pharmaceuticals in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for ARAKODA® (tafenoquine) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements.
Tune in today on Apple, Spotify, or YouTube. You can find the library of the Lyme Time Podcast at TheTickChicks.com.
To learn more about 60 Degrees Pharmaceuticals, click HERE.
Wishing you good health.
Love,
Ali
